|
**Overview**: **Hypertension Health Screen Profile****Introduction**: The Hypertension Health Screen Profile is a diagnostic tool designed to screen for hypertension causes using serum and urine samples. Associated with conditions like essential hypertension and secondary hypertension, these disorders present with high blood pressure, headache, and severe complications if untreated, particularly in individuals with cardiovascular concerns. Per the 2023 Biochemistry and Clinical Pathology guidelines, the test employs biochemistry and clinical pathology with spectrophotometry and microscopy technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for cardiovascular screening in clinical settings. This diagnostic falls under cardiovascular screening and targets individuals with suspected hypertension, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its dual-sample approach ensures reliable detection.**Other Names**: Hyper Hlth Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry and clinical pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1990s by metabolic labs, this test advanced hypertension screening.**Purpose**: The test screens for 22 parameters including total cholesterol to guide hypertension assessment, assess metabolic and renal function, and inform treatment and prevention strategies.**Test Parameters**: 1. Total Cholesterol, 2. HDL, 3. LDL, 4. Triglycerides, 5. Creatinine, 6. Urea, 7. Sodium, 8. Potassium, 9. Chloride, 10. Calcium, 11. Phosphorus, 12. Uric Acid, 13. Glucose, 14. HbA1c, 15. Aldosterone, 16. Renin, 17. Cortisol, 18. Urine Protein, 19. Urine Creatinine, 20. Urine Albumin/Creatinine Ratio, 21. Urine Sodium, 22. Urine Potassium.**Pretest Condition**: Fasting 10-12 hours required; patients should report high blood pressure, headache, or recent cardiovascular symptoms.**Specimen**: 3 mL serum in 1 SST, 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours (Serum), 24 hours (Urine) with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days (Serum, Urine) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months (Serum, Urine) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on high blood pressure, headache, prior cardiovascular reactions, or family history of hypertension, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated hypertension including stroke, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using spectrophotometry and microscopy and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent medication use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible hypertension causes, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in cardiology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: ECG or renal ultrasound for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in acute illness, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Biochemistry and Clinical Pathology Guidelines 2023, Journal of Cardiology 2024, Chemistry 2025. |
